{
    "clinical_study": {
        "@rank": "107452", 
        "arm_group": {
            "arm_group_label": "Treatment-Naive or Prior Partial/Null Response", 
            "arm_group_type": "Experimental", 
            "description": "telaprevir + Peginterferon alfa-2b +  Ribavirin"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the safety, efficacy, and pharmacokinetics in a\n      carefully monitored cohort of pediatric subjects infected with HCV on a telaprevir-based\n      regimen in Part A and with dose adjustments if needed before Part B."
        }, 
        "brief_title": "An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus", 
        "completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis C", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis C"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males or females ages 3 to 17 years of age\n\n          -  Chronic hepatitis C\n\n          -  Hepatitis C virus genotype 1a or b at the Screening Visit\n\n          -  Subject is judged to be in good health (besides HCV infection) in the opinion of the\n             investigator.\n\n          -  Signed ICF, and where appropriate, signed Assent Form\n\n        Exclusion Criteria:\n\n          -  History of or prior evidence of a medical condition associated with chronic liver\n             disease other than HCV\n\n          -  Body weight <15 kg or >90 kg\n\n          -  Prior evidence of hepatic decompensation\n\n          -  Contraindications to Peg-IFN/RBV\n\n          -  History or other evidence of severe retinopathy or clinically significant\n             ophthalmological disorder\n\n          -  History of non-genotype 1 HCV\n\n          -  Participation in investigational drug study as described in Study Protocol\n\n          -  Use of prohibited drugs within 7 days or 5 half-lives before the first dose of study\n             drug"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "3 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01701063", 
            "org_study_id": "VX11-950-118"
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment-Naive or Prior Partial/Null Response", 
                "description": "100- and 250-mg chewable tablets or 375-mg film-coated tablets for oral administration", 
                "intervention_name": "Telaprevir", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment-Naive or Prior Partial/Null Response", 
                "description": "50 \u03bcg/0.5 mL, 80 \u03bcg/0.5 mL, 120 \u03bcg/0.5 mL, or 150 \u03bcg/0.5 mL for subcutaneous (SC) injection", 
                "intervention_name": "Peginterferon alfa-2b", 
                "intervention_type": "Drug", 
                "other_name": "PegIntron\u00ae"
            }, 
            {
                "arm_group_label": "Treatment-Naive or Prior Partial/Null Response", 
                "description": "200-mg capsules or 40-mg/mL solution for oral administration", 
                "intervention_name": "Ribavirin", 
                "intervention_type": "Drug", 
                "other_name": "Rebetol\u00ae"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Ribavirin", 
                "Peginterferon alfa-2b", 
                "Interferon-alpha"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 26, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Phoenix", 
                        "country": "United States", 
                        "state": "Arizona"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gainesville", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bronx", 
                        "country": "United States", 
                        "state": "New York"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas"
                    }
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brussel", 
                        "country": "Belgium"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bruxelles", 
                        "country": "Belgium"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Erlangen", 
                        "country": "Germany"
                    }
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wuppertal", 
                        "country": "Germany"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Padova", 
                        "country": "Italy"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Parma", 
                        "country": "Italy"
                    }
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pisa", 
                        "country": "Italy"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Esplugues de Llobregat", 
                        "country": "Spain"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United Kingdom"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leeds", 
                        "country": "United Kingdom"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Belgium", 
                "Germany", 
                "Italy", 
                "Spain", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Two-Part, Open-Label, Single-Arm Phase 1/2 Study of Safety, Pharmacokinetics, and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Aged 3 to 17 Infected With Genotype 1 Hepatitis C Virus", 
        "other_outcome": [
            {
                "description": "height, weight, and body mass index[BMI]", 
                "measure": "Growth and development parameters", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years after EOT"
            }, 
            {
                "description": "Child Health Questionnaire [CHQ]", 
                "measure": "Quality of life parameters", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years after EOT"
            }, 
            {
                "description": "Children's Depression Inventory 2 [CDI 2TM]", 
                "measure": "Depression parameters", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years after EOT"
            }
        ], 
        "overall_contact": {
            "email": "medicalinfo@vrtx.com", 
            "last_name": "Central Contact Center", 
            "phone": "617-341-6777"
        }, 
        "overall_official": {
            "affiliation": "Vertex Pharmaceuticals Incorporated", 
            "last_name": "Medical Monitor", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Safety parameters, including AEs, study drug modifications or discontinuations, clinical laboratory values, vital signs, and electrocardiogram (ECG) assessments", 
            "safety_issue": "Yes", 
            "time_frame": "Up to week 52"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01701063"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Proportion of subjects who achieve undetectable HCV RNA 12 weeks after the last planned dose of study drug (SVR12)", 
                "safety_issue": "No", 
                "time_frame": "Up to week 60"
            }, 
            {
                "measure": "Proportion of subjects who achieve undetectable HCV RNA 24 weeks after the last planned dose of study drug (SVR24)", 
                "safety_issue": "No", 
                "time_frame": "Up to week 72"
            }, 
            {
                "measure": "Proportion of subjects who achieve undetectable HCV RNA at Week 4, at Week 12, at both Weeks 4 and 12 (eRVR), and at the planned end of treatment (EOT)", 
                "safety_issue": "No", 
                "time_frame": "Up to week 48"
            }, 
            {
                "measure": "Proportion of subjects with on-treatment virologic failure, defined as either meeting a futility rule or completing the assigned treatment duration with detectable HCV RNA at the EOT", 
                "safety_issue": "No", 
                "time_frame": "Up to week 48"
            }, 
            {
                "measure": "Proportion of subjects with virological relapse, defined as having undetectable HCV RNA at planned EOT followed by detectable HCV RNA after planned EOT", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years after EOT"
            }, 
            {
                "description": "Observed plasma concentration [Cmax], time to max plasma concentration [tmax], area under the plasma concentration versus time curve [AUC], and [t1/2]", 
                "measure": "Part A only, then Part B: Composite of Pharmacokinetics of telaprevir", 
                "safety_issue": "No", 
                "time_frame": "At Day 7, Week 2, Week 4, and Week 8"
            }, 
            {
                "measure": "Changes from baseline in the amino acid sequence of the HCV NS3\u20224A protease", 
                "safety_issue": "No", 
                "time_frame": "Up to week 52"
            }
        ], 
        "source": "Vertex Pharmaceuticals Incorporated", 
        "sponsors": {
            "collaborator": {
                "agency": "Janssen Pharmaceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Vertex Pharmaceuticals Incorporated", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}